Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNG | P07510 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRND | Q07001 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27770756 | 0.85 | TSHR (0.44) | CYP3A4GAAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL27056087 | 0.83 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL24222172 | 0.82 | PRSS1 (0.45) | HPGDNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2492152 | 0.82 | TSHR (0.47) | HPGDNPC1RAB9AMEN1KMT2A | |
| Hydrogen Sulfide SCHEMBL28190447 | 0.81 | TSHR (0.45) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8282801 | 0.79 | HDAC1 (0.49) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL869560 | 0.79 | TAS1R3 (0.40) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL14956485 | 0.79 | TP53 (0.31) | SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL979455 | 0.78 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL31394687 | 0.78 | TSHR (0.42) | SLC6A2SLC6A4SLC6A3HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2025-09-23 | — | — | US | disclosed |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-12-05 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| CN-111542526-A | Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor | 因赛特公司 | 2020-08-14 | — | — | CN | disclosed |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | SLC6A2 3774/4885SLC6A4 4178/4885SLC6A3 3592/4885 |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3969/4885SLC6A4 4518/4885SLC6A3 2716/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | SLC6A2 4056/4885SLC6A4 4430/4885SLC6A3 2493/4885 |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3925/4885SLC6A4 4460/4885SLC6A3 2632/4885 |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3C2B | SLC6A2 2597/4885SLC6A4 3315/4885SLC6A3 1116/4885 |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3925/4885SLC6A4 4460/4885SLC6A3 2632/4885 |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | SLC6A2 4056/4885SLC6A4 4430/4885SLC6A3 2493/4885 |
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3969/4885SLC6A4 4518/4885SLC6A3 2716/4885 |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3CD, PIK3CG | SLC6A2 3660/4885SLC6A4 3958/4885SLC6A3 3420/4885 |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | SLC6A2 4060/4885SLC6A4 4505/4885SLC6A3 2672/4885 |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3925/4885SLC6A4 4460/4885SLC6A3 2632/4885 |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | SLC6A2 3925/4885SLC6A4 4460/4885SLC6A3 2632/4885 |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | SLC6A2 4060/4885SLC6A4 4505/4885SLC6A3 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.